Search for other papers by Fahimeh Sadat Gholam-Mostafaei in
Current site
Google Scholar
PubMed
Search for other papers by Abbas Yadegar in
Current site
Google Scholar
PubMed
Search for other papers by Hamid Asadzadeh Aghdaei in
Current site
Google Scholar
PubMed
Search for other papers by Shabnam Shahrokh in
Current site
Google Scholar
PubMed
Search for other papers by Nasser Ebrahimi Daryani in
Current site
Google Scholar
PubMed
Search for other papers by Mohammad Reza Zali in
Current site
Google Scholar
PubMed
Abstract
Treatment of recurrent Clostridioides difficile infection (rCDI) has emerged as an important management dilemma particularly in patients with underlying inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) has been used as a safe and highly effective treatment option for rCDI refractory to standard antibiotic therapies. The aim of this study was to report the efficacy of FMT in Iranian rCDI patients with concurrent IBD. A total of seven consecutive patients with ulcerative colitis (UC) who had experienced 3 episodes of rCDI were enrolled in this study. All patients received at least a single FMT administered during colonoscopy by direct infusion of minimally processed donor stool. Patients were followed for a minimum of 6 months for assessment of treatment efficacy and adverse events (AEs) attributable to FMT. All 7 UC patients (100%) experienced a durable clinical response to a single FMT following 2 months after the procedure. One patient received a second FMT in which a successful resolution of rCDI was ultimately achieved. No serious AEs from FMT were noted. FMT through colonoscopy was a safe, simple and effective alternative treatment approach for rCDI in patients with underlying IBD. However, its use and efficacy should be pursued in long-term prospective controlled trials.
-
1.
Oligschlaeger Y , Yadati T , Houben T , Condello Olivan CM , Shiri-Sverdlov R . Inflammatory bowel disease: a stressed “gut/feeling”. Cells 2019; 8(7).
-
2.
Taghavi SA , Safarpour AR , Hosseini SV , Noroozi H , Safarpour M , Rahimikazerooni S . Epidemiology of inflammatory bowel diseases (IBD) in Iran: a review of 740 patients in Fars Province, Southern Iran. Ann Colorectal Res 2013; 1(1): 17–22.
-
3.
Azimirad M , Krutova M , Balaii H , Kodori M , Shahrokh S , Azizi O , et al.. Coexistence of Clostridioides difficile and Staphylococcus aureus in gut of Iranian outpatients with underlying inflammatory bowel disease. Anaerobe 2019; 61: 102–13.
-
4.
Zhang YZ , Li YY . Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20(1): 91–9.
-
5.
Nguyen GC , Kaplan GG , Harris ML , Brant SR . A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103(6): 1443.
-
6.
Azimirad M , Krutova M , Yadegar A , Shahrokh S , Olfatifar M , Aghdaei HA , et al.. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. Emerg Microbes Infect 2020: 1–39.
-
7.
Gholam-Mostafaei FS , Yadegar A , Aghdaei HA , Azimirad M , Daryani NE , Zali MR . Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease. Curr Res Transl Med 2020; 68(3): 125–30.
-
8.
McFarland LV , Elmer GW , Surawicz CM . Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97(7): 1769.
-
9.
Hopkins RJ , Wilson RB . Treatment of recurrent Clostridium difficile colitis: a narrative review. Gastroenterol Rep 2018; 6(1): 21–8.
-
10.
Kelsen JR , Kim J , Latta D , Smathers S , McGowan KL , Zaoutis T , et al.. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17(1): 50–5.
-
11.
Manichanh C , Rigottier-Gois L , Bonnaud E , Gloux K , Pelletier E , Frangeul L , et al.. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55(2): 205–11.
-
12.
Morgan XC , Tickle TL , Sokol H , Gevers D , Devaney KL , Ward DV , et al.. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13(9): R79.
-
13.
Fischer M , Sipe B , Cheng YW , Phelps E , Rogers N , Sagi S , et al.. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017; 8(3): 289–302.
-
14.
Brandt LJ , Aroniadis OC , Mellow M , Kanatzar A , Kelly C , Park T , et al.. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107(7): 1079–87.
-
15.
Azimirad M , Yadegar A , Asadzadeh Aghdaei H , Kelly CR . Enterotoxigenic Clostridium perfringens infection as an adverse event after faecal microbiota transplantation in two patients with ulcerative colitis and recurrent Clostridium difficile infection: a neglected agent in donor screening. J Crohns Colitis 2019; 13(7): 960–1.
-
16.
Anderson JL , Edney RJ , Whelan K . Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36(6): 503–16.
-
17.
McDonald LC , Gerding DN , Johnson S , Bakken JS , Carroll KC , Coffin SE , et al.. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare Epidemiology of America (SHEA). Clin Infect Dis Official Pub Infect Dis Soc America 2018; 66(7): e1–48.
-
18.
Surawicz CM , Brandt LJ , Binion DG , Ananthakrishnan AN , Curry SR , Gilligan PH , et al.. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol; 108(4): 478–98. quiz 499 (2013).
-
19.
Bakken JS , Borody T , Brandt LJ , Brill JV , Demarco DC , Franzos MA , et al.. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9(12): 1044–9.
-
20.
Newman KM , Rank KM , Vaughn BP , Khoruts A . Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes 2017; 8(3): 303–9.
-
21.
Xu D , Chen VL , Steiner CA , Berinstein JA , Eswaran S , Waljee AK , et al.. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2019; 114(7): 1043–50.
-
22.
Allegretti JR , Kassam Z , Carrellas M , Mullish BH , Marchesi JR , Pechlivanis A , et al.. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol 2019; 114(7): 1071–9.
-
23.
Xu MQ , Cao HL , Wang WQ , Wang S , Cao XC , Yan F , et al.. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015; 21(1): 102–11.
-
24.
Wortelboer K , Nieuwdorp M , Herrema H . Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine 2019; 44: 716–29.
-
25.
Orel R , Kamhi Trop T . Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol 2014; 20(33): 11505–24.
-
26.
Mills JP , Rao K , Young VB . Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol 2018; 34(1): 3–10.
-
27.
Chin SM , Sauk J , Mahabamunuge J , Kaplan JL , Hohmann EL , Khalili H . Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience. Clin Gastroenterol Hepatol 2017; 15(4): 597–9.
-
28.
Fischer M , Kao D , Kelly C , Kuchipudi A , Jafri S-M , Blumenkehl M , et al.. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016; 22(10): 2402–9.
-
29.
Rohlke F , Surawicz CM , Stollman N . Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010; 44(8): 567–70.
-
30.
Kelly CR , de Leon L , Jasutkar N . Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46(2): 145–9.
-
31.
Gough E , Shaikh H , Manges AR . Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53(10): 994–1002.
-
32.
Aas J , Gessert CE , Bakken JS . Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36(5): 580–5.
-
33.
Agrawal M , Aroniadis OC , Brandt LJ , Kelly C , Freeman S , Surawicz C , et al.. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 2016; 50(5): 403–7.
-
34.
Kronman MP , Nielson HJ , Adler AL , Giefer MJ , Wahbeh G , Singh N , et al.. Fecal microbiota transplantation via nasogastric tube for recurrent Clostridium difficile infection in pediatric patients. J Pediatr Gastroenterol Nutr 2015; 60(1): 23–6.
-
35.
Ramai D , Zakhia K , Ofosu A , Ofori E , Reddy M . Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Ann Gastroenterol 2019; 32(1): 30–8.
-
36.
Wilson BC , Vatanen T , Cutfield WS , O'Sullivan JM . The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol 2019; 9(2).
-
37.
Kassam Z , Lee CH , Yuan Y , Hunt RH . Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108(4): 500.
-
38.
Osman M , Stoltzner Z , O'Brien K , Ling K , Koelsch E , Dubois N , et al.. Donor efficacy in fecal microbiota transplantation for recurrent Clostridium difficile: evidence from a 1,999-patient cohort. Open Forum Infect Dis 2016; 3(suppl_1).
-
39.
Petrof EO , Gloor GB , Vanner SJ , Weese SJ , Carter D , Daigneault MC , et al.. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 2013; 1(1): 3.
-
40.
Emanuelsson F , Claesson BE , Ljungstrom L , Tvede M , Ung KA . Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis 2014; 46(2): 89–97.
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 1.3 |
| Rank by Impact Factor | Q4 (Immunology) |
| Journal Citation Indicator | 0.31 |
| Scopus | |
| CiteScore | 2.3 |
| CiteScore rank | Q3 (Infectious Diseases) |
| SNIP | 0.389 |
| Scimago | |
| SJR index | 0.308 |
| SJR Q rank | Q3 |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article (only for OA publications) |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 772 EUR / 848 USD Print + online subscription: 860 EUR / 944 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Apr 2024 | 52 | 0 | 0 |
| May 2024 | 27 | 1 | 1 |
| Jun 2024 | 33 | 0 | 1 |
| Jul 2024 | 72 | 0 | 0 |
| Aug 2024 | 82 | 0 | 0 |
| Sep 2024 | 81 | 0 | 0 |
| Oct 2024 | 36 | 0 | 0 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.